Atlas Trials

PrECOG, LLC.

19 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch PrECOG, LLC.

RecordFirmDate
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer (NCT07637513)PrECOG, LLC.2027-01-01
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma (NCT07285239)PrECOG, LLC.2026-09-01
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer (NCT07057791)PrECOG, LLC.2026-03-30
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients (NCT06538038)PrECOG, LLC.2024-09-17
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (NCT04334759)PrECOG, LLC.2021-02-18
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age (NCT03834688)PrECOG, LLC.2020-01-13
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (NCT03836209)PrECOG, LLC.2019-12-06
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (NCT03532451)PrECOG, LLC.2019-03-22
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma (NCT03323151)PrECOG, LLC.2018-08-13
Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy (NCT03113422)PrECOG, LLC.2017-12-27

Track PrECOG, LLC. automatically

Every clearance here is in the API, with alerts when new ones post.